Allianz Asset Management GmbH acquired a new stake in shares of Genomic Health (NASDAQ:GHDX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 75,675 shares of the medical research company’s stock, valued at approximately $2,588,000. Allianz Asset Management GmbH owned 0.22% of Genomic Health at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GHDX. Citadel Advisors LLC increased its position in shares of Genomic Health by 269.5% during the third quarter. Citadel Advisors LLC now owns 93,803 shares of the medical research company’s stock valued at $3,010,000 after purchasing an additional 68,418 shares during the period. Aurora Investment Counsel bought a new stake in shares of Genomic Health during the fourth quarter valued at approximately $1,879,000. American Century Companies Inc. increased its position in shares of Genomic Health by 40.1% during the third quarter. American Century Companies Inc. now owns 178,286 shares of the medical research company’s stock valued at $5,721,000 after purchasing an additional 50,992 shares during the period. First Manhattan Co. increased its position in shares of Genomic Health by 58.4% during the fourth quarter. First Manhattan Co. now owns 110,900 shares of the medical research company’s stock valued at $3,792,000 after purchasing an additional 40,900 shares during the period. Finally, Cowen Prime Services LLC increased its position in shares of Genomic Health by 40.9% during the third quarter. Cowen Prime Services LLC now owns 124,864 shares of the medical research company’s stock valued at $4,007,000 after purchasing an additional 36,229 shares during the period. Institutional investors and hedge funds own 91.18% of the company’s stock.
Shares of Genomic Health stock opened at $32.47 on Thursday. The company has a market capitalization of $1,152.28, a price-to-earnings ratio of -295.18 and a beta of 0.61. Genomic Health has a one year low of $26.54 and a one year high of $37.50.
GHDX has been the topic of a number of research reports. Zacks Investment Research cut Genomic Health from a “hold” rating to a “strong sell” rating in a research report on Friday, March 9th. Barclays restated a “sell” rating and set a $28.00 price objective on shares of Genomic Health in a research report on Monday, January 8th. Canaccord Genuity restated a “buy” rating and set a $42.00 price objective on shares of Genomic Health in a research report on Tuesday, January 16th. JPMorgan Chase & Co. cut Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 price objective on the stock. in a research report on Wednesday, December 13th. Finally, ValuEngine upgraded Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, December 15th. Four analysts have rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. Genomic Health presently has a consensus rating of “Hold” and an average target price of $32.67.
In other Genomic Health news, COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $35.51, for a total value of $177,550.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Phillip G. Febbo sold 4,942 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $32.84, for a total value of $162,295.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,946 shares of company stock worth $1,449,902. 46.20% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://weekherald.com/2018/03/22/allianz-asset-management-gmbh-invests-2-59-million-in-genomic-health-ghdx-stock.html.
Genomic Health Profile
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health (NASDAQ:GHDX).
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.